EUCTR2007-006119-22-IT进行中（未招募）不适用
Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours(TET) or Histiocitosi X (LCH) with Imatinib Mesylate. - TETIMAX
IVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II0 个研究点开始时间: 2008年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •2.TET or LCH confirmed by istological analisys
- •3.Patients that have received at least one line of treatment with progression of disease
- •4.Immunoistochemical evaluation
- •expression of cKIT, PDGFRα, PDGFRβ, m-TOR, p-AKT in LCH patints ,
- •expression of EGFR, c-KIT, COX-in TET patients.
- •5.Age from 18 to 75 years old
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnat womeni, childbearing or in fertile period without anticonceptional measures
- •2.Non measurable lesion as unique site of disease
- •3. Important disease that can give at the patient high risk of injury
研究者
相似试验
尚未招募
2 期
effect of Chitrakadi Tail Basti in SciaticaCTRI/2022/02/040271DR SUSHMITA GAJENDRA GOSAVI
进行中（未招募）
不适用
Clinical trial to determinate viral load in seminal fluid in HIV-positive patients without previous treatmentHIV-1 infectionMedDRA version: 17.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-001348-39-ESFundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI)
尚未招募
2 期
To study the effect of panchlavan siddha ghritpan in Allergic rhinitisCTRI/2020/10/028224Aarogyashala Rugnalaya Nashik
尚未招募
2 期
To study the effect of eladi ointmentCTRI/2020/09/028022Ayurved Mahavidyalaya Nashik
进行中（未招募）
1 期
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25